3 Result: Seagen
Momentum Builds: Bladder Cancer Trial Data Boost Seagen
September 22nd, 2023
Astellas Pharma Inc. and Seagen Inc. (Nasdaq: SGEN) have reported promising results from the Phase 3 EV-302 clinical trial (KEYNOTE-A39) for PADCEV (enfortumab vedotin-ejfv) combined with Merck & Co., Inc.'s (NYSE: MRK) KEYTRUDA (pembrolizumab) versu. Read more
Seagen and Genmab: Breakthrough Cervical Cancer Trial Outcome
September 04th, 2023
Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) have reported a significant breakthrough in the Phase 3 innovaTV 301 global trial for recurrent or metastatic cervical cancer. Patients treated with TIVDAK (tisotumab vedotin-tftv) showed an im. Read more
Breaking: FTC Seeks More Info on Pfizer's Seagen Merger Plan
July 15th, 2023
Seagen Inc. (Nasdaq: SGEN) and Pfizer Inc. (NYSE: PFE) have encountered a regulatory hurdle in their planned merger. According to a regulatory filing with the SEC, both companies received a Second Request from the Federal Trade Commission (FTC) on Ju. Read more
Want To Find Some News?
News By Industries
Recent Post
-
FTC Takes Action to Prevent Anticompetitive Arrangement in Beretta, Ruger Deal
September 16th, 2026Why Opponent Preparation Matters for Post-Graduate Athletes
September 16th, 2026The Work Behind the Game: How Football Teams Prepare to Compete
September 15th, 2026NJCP Operates on a Prep Model Built Around a Full Season
September 14th, 2026Earnings Preview: High Tide, Kestra Medical, and RF Industries in Focus
September 12th, 2026
Member Login